Head-to-head evidence
LW402 vs VC005
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK1 · full Atopic Dermatitis pipeline
LW402
Developed by Shanghai Longwood Biopharmaceuticals
NCT07186387 · Phase 2 · completed
The trial was randomized and quadruple-blind, used a placebo control, and enrolled 144 participants; its primary endpoint was a clinical disease-response measure (EASI-50). Because the primary comparison result is not available, the study provides well-designed but incomplete evidence rather than evidence of a confirmed favorable effect.
Next expected readout: March 2028 · NCT07370909 (registry estimate)
VC005
Developed by Jiangsu Vcare Pharmatech and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT07598383 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LW402's landscape · VC005's landscape